- Event to be webcast on Thursday, September 23 at 11:00 a.m. ET
- Phase 3 ROMAN trial of avasopasem manganese, Galera’s lead candidate for SOM in patients with head and neck cancer, expected to read out in 4Q 2021
MALVERN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that the Company will host a virtual Key Opinion Leader event on radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer on Thursday, September 23 at 11:00 a.m. ET.
Dr. Carryn Anderson, Clinical Associate Professor of Radiation Oncology at the University of Iowa, will provide a review of the current clinical treatment paradigm for patients with locally advanced head and neck cancer, including the use of intensity-modulated radiation therapy.
Dr. Anderson’s presentation will be followed by a video from a head and neck cancer survivor on his experience with SOM and a presentation from Galera’s President and CEO, Mel Sorensen, M.D., with an overview of the SOM market in patients with head and neck cancer.
The live audio webcast of the event will be accessible from the News & Events section of the Investors page of Galera’s website at investors.galeratx.com. Individuals can participate in an interactive Q&A session by submitting...
Read Full Story: https://www.biospace.com/article/releases/galera-to-host-virtual-key-opinion-leader-event-on-radiotherapy-induced-severe-oral-mucositis-som-in-patients-with-head-and-neck-cancer/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.
